Innate Pharma S.A. ADS
Symbol: IPHA (NASDAQ)
2.09
▲ (1.96%) 0.040
Company Description:
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Key Stats
- Today's Open: $2.04
- Today's High: $2.085
- Today's Low: $1.995
- Today's Volume: 29.63K
- Yesterday Close: $2.045
- Yesterday High: $2.045
- Yesterday Low: $2.03
- Yesterday Volume: 2.13K
- Last Min Volume: 1
- Last Min High: $2.085
- Last Min Low: $2.085
- Last Min VWAP: $2.085
Company Profile
- Name: Innate Pharma S.A. ADS
- Website: https://www.innate-pharma.com
- Listed Date: 2015-09-09
- Location: ,
- Market Status: Active
- CIK Number: 0001598599
- SIC Code:
- SIC description:
- Market Cap: $188.02M
- Round Lot: 100
- Outstanding Shares: 92.17M
- Asset Type: ADRC
RECENT FILINGS FOR IPHA
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 6-K | View |
| 2025-09-02 | 6-K | View |
| 2025-08-04 | 6-K | View |
| 2025-07-29 | 6-K | View |
| 2025-07-07 | 6-K | View |
| 2025-06-17 | 6-K | View |
| 2025-06-13 | 6-K | View |
| 2025-05-30 | 144 | View |
| 2025-05-27 | 6-K | View |
| 2025-05-23 | 6-K | View |
| 2025-05-23 | 6-K | View |
| 2025-05-19 | 6-K | View |
| 2025-05-15 | 6-K | View |
| 2025-05-13 | 6-K | View |
| 2025-05-12 | 6-K | View |
| 2025-05-07 | SCHEDULE 13D/A | View |
| 2025-05-06 | 6-K | View |
| 2025-04-30 | 6-K | View |
| 2025-04-30 | 20-F | View |
| 2025-04-29 | SCHEDULE 13G/A | View |
Latest News on IPHA